Natural product-derived therapy for improving cardiac contractility and attenuating pathogenesis associated with Myocardial infarction: A pharmaceutical mixture encompassing Withaferin A, Hesperidin and Isoorientin (WAHI) decreases GRK2 (G Protein-Coupled Receptor Kinase 2) and GM-CSF (Granulocyte-macrophage colony-stimulating factor) expression, increases cardiac contractility, inhibits undue leucocyte activation and invasion, suppresses recruitment of inflammatory cells, inhibits left ventricular rupture, promotes heart healing and inhibits glucose intolerance, via up regulation of its target gene, 23/December/2017, 2.13 am

Natural product-based therapy for Deafness: A therapeutic mix encompassing Lycopene(LYC), Cholecalciferol, and DIM (LYCCAD)  increases the expression of ATG5 (Autophagy-related 5), prevents aggregation of proteins in inclusion bodies, inhibits hair cell degeneration,  improves hearing loss via up regulation of its target genes, 23/December/2017, 1.58 am
December 22, 2017
Activation of the PD-1 pathway for Pain therapy: Lycopene (LYC), isolated from Gac, Guava, Tomatoes, and among others,  increases the expression of PD-L1, attenuates acutes and chronic pain, and suppresses mechanical and thermal hypersensitivity and inhibits nociceptive neuron excitability via up-regulation of its target gene, 23/December/2017, 2.24 am
December 22, 2017
Show all

Introduction: What they say:

A recent study, from Department of Medicine, Division of Cardiology, Dept of Cell Biology, and Department of Molecular Genetics, Duke University Medical Center, Durham, North Carolina, USA, shows that “Mdm2 regulates cardiac contractility by inhibiting GRK2-mediated desensitization of ß-adrenergic receptor signaling.” This study was published, in the 7 September 2017 issue of JCI (Journal of Clinical Investigation) Insight, by Prof Shenoy, Jean-Charles PY and others.


What we say:

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Natural product-derived therapy for improving cardiac contractility and attenuating pathogenesis associated with Myocardial infarction: A pharmaceutical mixture encompassing Withaferin A, Hesperidin and Isoorientin (WAHI) decreases GRK2 (G Protein-Coupled Receptor Kinase 2) and GM-CSF (Granulocyte-macrophage colony-stimulating factor) expression, increases cardiac contractility, inhibits undue leucocyte activation and invasion, suppresses recruitment of inflammatory cells, inhibits left ventricular rupture, promotes heart healing and inhibits glucose intolerance, via up regulation of its target gene


From Significance of the study to Public Health relevance:

Given that: (1) cardiovascular disease is the leading cause of death worldwide; (2) the raise of death rate, due to cardiovascular disease, has increased from 123 lakhs in 1990 to 173 lakhs in 2013; (3) 85% of people over 80 years are susceptible to cardiovascular diseases;(4) in India, in 2004, 14.6 lakhs deaths (14% of total deaths) were due to ischemic heart disease; (3) the death due to cardiovascular disease is higher in low-to-middle income countries compared to developed countries; (4) the global economic cost spent in the treatment of cardiovascular disease in 2011 was little more than 10 billion US dollars; (5) an alarming number of people, such as 230 lakhs people, will die from cardiovascular diseases each year by 2030, there is an urgent need to find: (i) a way to induce regeneration of cardiomyocytes that were lost in Myocardial patients; (ii) a cheaper alternative to the existing expensive drugs; and (iv) a side-effect-free Natural product-based drug.


What is known?

Earlier studies showed that MDM2, a RING domain-containing E3 ubiquitin ligase and widely known negative regulator of tumor suppressor p53, ubiquitinates G protein-coupled receptor kinase 2 (GRK2) and ß-arrestin2. And thereby, control ß-adrenergic receptor (ßAR) signaling and endocytosis.

Prof Shenoy’s research team has shown recently that: (1) MDM2 regulates cardiac ß1AR signaling; (2) in response to isoproterenol treatment, cAMP levels are increased in left ventricles of Wild-type mice, but not in Mdm2/p53-KO mice; (3) isoproterenol treatment also results in impairment of calcium signalling in left ventricles of Wild-type mice, but not in Mdm2/p53-KO mice; (4) GRK2 levels are increased in Mdm2/p53-KO mice compared to Wild-type mice; (5) GRK2 polyubiquitination is impaired in Mdm2/p53-KO hearts; (6) deleting MDM2 in Cardiomyocytes results in a) increased expression of GRK2; b) impaired cardiac function; c) high mortality; and d) non-responsiveness to ßAR; and (7) induction of MDM2 gene in Mdm2/p53-KO mice rescues ß1AR-induced cardiac contractility, suggesting that either increased expression of MDM2 or attenuation of GRK2 expression in cardiomyocytes may enhance cardiac contractility and function by attenuating GRK2-mediated desensitization of ßAR signalling.


From Research Findings to Therapeutic Opportunity:

This study provides a natural product-based therapy for promoting cardiac contractility and attenuating pathogenesis-associated with Myocardial infarction.

Withaferin A, Hesperidin and Isoorientin (WAHI), by increasing the expression of its target genes, it may decrease the expression of GRK2 and GM-CSF (fig.1). Thereby, it may: (i) sensitize ßAR signalling; (ii) increase cardiac contractility; (iii) increase sympatholytic activity; (iv) improve cardiac function; (v) stall recruitment of inflammatory and proteolytic cells;(vi) inhibit accumulation of excessive amount of neutrophils and monocytes near the damaged myocardium; (vii) inhibit left ventricular rupture and remodelling; (viii) suppress leukocyte supply chain; (ix) control excessive inflammatory reaction; (x) inhibit cardiac hypertrophy; (xi) inhibit cardiac ageing; (xii) increase glucose tolerance; (xiii) augment insulin sensitivity; (xiv) promote vascular endothelial function; (xv) attenuate Hypertension; (xvi) promote Weight loss and lean mass; (xvii) extend Lifespan (figs. 1-3).

Figure 1. A pharmaceutical mixture encompassing Withaferin A, Hesperidin and Isoorientin (WAHI)  functions as a Cardioprotective agent. Mechanistic insights into how WAHI decreases the expression of GM-CSF and CRK2 and other genes that promote pathogenesis-associated with myocardial infarction, while increasing the expression of cardioprotective genes that promote cardiomyocyte survival and regeneration

Figure 2. WAHI functions as a Cardioprotective agent through down regulation of GRK2 and GM-CSF and up regulation of a number of proteins that promote cardiomyocyte survival and regeneration.

Together, this study suggests that pharmacological formulations encompassing Withaferin A, Hesperidin and Isoorientin (WAHI) or their analogs, either alone or in combination with other compounds,” may be used to increase cardiac contractility and heal damaged cardiac tissue after myocardial infarction (fig. 1).

.


Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How  Withaferin A, Hesperidin and Isoorientin (WAHI) decreases the expression of GRK2 and GM-CSF, inhibits inflammatory leukocyte recruitment, and attenuates the pathogenesis associated with myocardial infarction

Amount: $ 750 #

# Research cooperation

For purchase and payment details, you may reach us at admin@genomediscovery.org


References:

Web: http://genomediscovery.org or http://newbioideas.com/

Citation: Boominathan, L., Natural product-derived therapy for improving cardiac contractility and attenuating pathogenesis associated with Myocardial infarction: A pharmaceutical mixture encompassing Withaferin A, Hesperidin and Isoorientin (WAHI) decreases GRK2 (G Protein-Coupled Receptor Kinase 2) and GM-CSF (Granulocyte-macrophage colony-stimulating factor) expression, increases cardiac contractility, inhibits undue leucocyte activation and invasion, suppresses recruitment of inflammatory cells, inhibits left ventricular rupture, promotes heart healing and inhibits glucose intolerance, via up regulation of its target gene, 23/December/2017, 2.13 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at admin@genomediscovery.org

Comments are closed.